The University Hospital Center of Coimbra (ULS de Coimbra) in Portugal has launched a project aimed at the early diagnosis of cognitive decline and Alzheimer's disease. This initiative seeks to improve the detection and treatment of these conditions. According to Inês Rosendo, director for Primary Health Care, the project includes evaluating the impact of a peripheral blood biomarker. This approach could be implemented in primary health care.
The ULS de Coimbra's Laboratory of Neurochemistry, part of the Neurology Department, was a pioneer in developing and validating a blood-based biomarker for Alzheimer's disease diagnosis. This method involves a simple blood test, streamlining the diagnostic process already used in neurology consultations. Natália António, director of Clinical Hospital Care, emphasized that early detection of dementia and Alzheimer's disease is crucial. It allows for earlier intervention and personalized clinical approaches, potentially improving patient outcomes.
The use of a precise and accessible biomarker, applied ethically and scientifically, will simplify the complex and time-consuming diagnostic process. It will also enable a more rigorous selection of patients with potential Alzheimer's disease. These patients can then be quickly referred to tertiary care. According to António, this will contribute to better patient outcomes and reduced cognitive decline.
The integrated program between primary and specialized care aims to raise awareness and enhance the training of involved healthcare professionals. It also seeks to promote effective coordination between the two levels of care. Isabel Santana, director of the Neurology Department, stated that the program's primary goal is to contribute to the early biological diagnosis of cognitive decline and Alzheimer's disease.
This project will provide better care for patients and allow primary care professionals to recognize the importance of memory complaints. They will be actively involved in a faster diagnosis process, working closely with specialized consultations. The possibility of earlier detection and promotion of equitable access to health care may improve patient outcomes and reduce the burden associated with cognitive decline.
The approach will impact the future organization of health care in this area within the ULS de Coimbra. The results could be replicated nationwide, generating new scientific data. The project aligns with Portugal's National Health Plan 2030, the Health Strategy for Dementia, and the National Health Plan for Dementia.
These initiatives are also in line with the World Health Organization's guidelines, which identify cognitive changes and dementia as a global priority. Alzheimer's disease and other dementias are the seventh leading cause of death worldwide and the leading cause of years lived with high disability. The ULS de Coimbra's project aims to address this significant health concern.
Key points
- Early detection of Alzheimer's disease through a blood biomarker
- Improved patient outcomes through personalized clinical approaches
- Enhanced coordination between primary and specialized care
